



RESEARCH

Open Access

KRAS and BRAF mutational status in colon cancer from Albanian patients

Daniela Martinetti¹, Rosario Costanzo¹, Shahin Kadare², Mehdiu Alimehmeti³, Cristina Colarossi⁴, Vincenzo Canzonieri⁵, Massimiliano Berretta⁶ and Lorenzo Memeo^{1,4*}

Abstract

Background: Numerous clinical studies have shown that anti-EGFR therapies are effective only in a subset of patients with colorectal cancer. Mutations in the KRAS and BRAF genes have been confirmed as negative predictors of the response to EGFR-targeted therapies.

In this study we evaluated KRAS and BRAF status in 159 colorectal cancer samples obtained from the University of Tirana.

Methods: We evaluated KRAS mutations in codons 12, 13, 61, 146 and in codon 600 of BRAF by direct sequencing. 90 patients were male (57%) and 69 female (43%); the patients' ages ranged from 17 to 85 (median 61.7). 24 patients were stage I, 36 stage II, 84 stage III and 15 stage IV.

Results: Out of the 159 cases, 28 (17.6%) showed KRAS mutation (13 G12D, 4 G12C, 4 G12V, 3 G12A, 2 G13 D, 1 G12S and 1 A146T), and 10 (6.3%) showed BRAF mutation (all V600E). No significant correlations between KRAS and BRAF mutations and various clinicopathological parameters was found.

This is the first report of KRAS and BRAF status in Albanian patients with colorectal carcinoma (CRC) and though the relatively small sample size might not provide enough statistics power.

Conclusions: The results of KRAS and BRAF mutation analysis could be used in the selection of patients for anti-EGFR therapy.

Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_187

Keywords: Colorectal cancer, KRAS, BRAF, Albania

Background

Colorectal cancer (CRC) is the third most common malignancy in men and women with an incidence of 1,234,000 cases contributing 10% of the total burden [1]. The incidence rates of colon cancer vary in various geographic locations with highest rates estimated in Australia/New Zealand and Western Europe [2].

The development of CRC is a multistep process that occurs because of the accumulation of several genetic alterations, including chromosomal abnormalities, gene mutations, and epigenetic modifications involving several

genes that regulate proliferation, differentiation, apoptosis, and angiogenesis [3,4].

Of the various genetic alterations, an important molecular target for metastatic CRC treatment is the epidermal growth factor receptor (EGFR). EGFR, a tyrosine kinase receptor belonging to the ErbB family, has been found to play a significant role in the pathogenesis of CRC by inducing downstream signaling pathways, such as the phosphatidylinositol-3-kinase/Akt and RAS/RAF/MAP-activated protein kinase (MAPK) pathways.

The EGFR is overexpressed in about 50-80% of CRCs and has been the focus of a new drug development [5] and antibodies targeting EGFR, such as cetuximab and panitumumab, have been examined for therapeutic efficacy in CRC patients [6].

* Correspondence: lorenzo.memeo@grupposamed.com

¹IOM Ricerca Srl, Catania, Italy

⁴Department of Experimental Oncology, Mediterranean Institute of Oncology, Via Penninazzo 7, 95029 Viagrande, Catania, Italy

Full list of author information is available at the end of the article

Oncogenic activation of signaling pathways downstream of the EGFR, as induced by mutated KRAS or BRAF, is important for the progression of colorectal cancer [7].

In human CRC, mutations in the *KRAS* gene have a frequency of around 30%-40% and were linked to poor outcomes, whereas mutations of the *BRAF* gene, a downstream molecule of KRAS, occur in only 5%-10% of patients with sporadic diseases. Mutations in the *KRAS* and *BRAF* genes are frequently found to be mutually exclusive in colorectal cancer [8,9].

Recently, any activating mutations in the *KRAS* gene has been proved to be predictor of response to epidermal growth factor receptor-targeted therapies, such as cetuximab and panitumumab, for patients with metastatic colorectal cancer [10].

Different somatic missense mutations in codons 12, 13, 61 and 146 are relevant for therapeutic efficacy of anti-EGFR therapy [10-14]. In addition, among colorectal tumors carrying wild-type *KRAS*, mutation of *BRAF* or *NRAS* or *PIK3CA* or loss of *PTEN* expression may be associated with resistance to EGFR-targeted monoclonal antibody treatment, although these additional biomarkers require further validation before incorporation into clinical practice [15].

Activating mutations of these oncogenes are point mutations (missense mutations) and they arise early during the development of colorectal cancer [16]. The activating mutations in *KRAS* oncogene are found mostly in codons 12 and 13 (>90%) but also affect codons 61 and 146 [12,13]. The most frequently observed types of mutations are G > A transitions, G > T and G > C transversions [17]. Identification of somatic-activating mutations of *BRAF* has been reported in various cancers, with by far the most common mutation being a 1799 T > A transversion leading to a Val600Glu (V600E) substitution [9].

Recent studies have demonstrated that a wild type BRAF is also required for response to panitumumab or cetuximab, suggesting that BRAF evaluation should be used together with KRAS for selecting the patients who could benefit from the anti-EGFR therapy [18,19].

In the present study, we detected mutations of KRAS and BRAF proto-oncogenes in tumoral tissue specimens in CRC patients of the Albanian population.

Correlations with various clinicopathological characteristics of patients were further analyzed. To our knowledge, we are the first to report the frequency and type of KRAS and BRAF mutations in Albanian patients with advanced CRC in order to introduce targeted therapy in the therapeutic modalities for management of this cancer in Albania.

Further researches are needed to determine how the racial differences and etiological factors can influence the spectrum and frequency of KRAS and BRAF mutations between different populations.

Methods

Patients and specimens

Tumor specimens used in this study were obtained from 159 CRC consecutive patients who underwent tumor resection at Tirana University Hospital during the period 2012–2013.

The study included 159 patients with histopathologically proven colorectal cancer; two pathologists independently confirmed the diagnosis.

Tumor stage was classified according to the Tumor, Node and Metastases (TNM) classification of the Union for International Cancer Control (UICC) staging.

The present study received the IRB approval from University of Tirana (#12; 21/02/2014).

Histological examination

Tumors were classified as well-, moderately or poorly differentiated adenocarcinoma in accordance with the World Health Organization Classification (Jass JR, Sobin LH. Histological typing of intestinal tumors. In World Health Organization, ed. International Histological Classification of Tumors, 2nd edn. Berlin: Springer, 1989; 29–40). Mucinous tumors were separately classified.

Additional histological features such as necrosis, tumor vascular invasion, stromal desmoplastic reaction and infiltrative versus expansive pattern of growth, have been evaluated but not considered as variable parameters for statistical analysis.

DNA isolation

Sections (5 micron) were cut from paraffin-embedded tumor tissue blocks and stained with haematoxylin & eosin (H&E) for histopathological examination.

For DNA isolation, 5 sections, each of 4 micron thickness, were used for each case. The H&E section was used as a reference and tumor tissue was macrodissected from the normal colonic epithelium and scraped off.

Genomic DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissue samples using the QIAamp DNA FFPE tissue kit (Qiagen) according to the manufacturer's recommendations and was amplified by PCR at KRAS exon 2, 3 and 4 and BRAF exon 15.

Analysis of KRAS and BRAF mutations

Mutation analysis of KRAS codons 12, 13, 61, 146 and BRAF codon 600 was carried out by direct sequencing of amplified PCR products.

PCR was performed using 50 ng genomic DNA as template. Each mixture contained 8 pmol of each primer. Primers were purchased from Roche Diagnostics Spa, Monza, Italia.

The reactions were performed in 1X GeneAmp 10X PCR Buffer II (Applied Biosystems), 0.25 μmol/L dNTPs,

2 mmol/L MgCl₂ solution, and 1.25 U AmpliTaq DNA Polymerase (Applied Biosystems, CA USA).

The amplification reactions were as follows: an initial denaturation cycle of 95°C for 5 min; 45 cycles of denaturation (95°C for 30 s), annealing (60°C for 30 s for KRAS exon 2, 55°C for 30 s for KRAS exon 3, 4 and 57°C for 30 s for BRAF exon 15), and elongation (72°C for 1 min); and a final extension cycle at 72°C for 5 min.

The PCR products were purified with 1 ml ExoI/SAP (37°C for 15 minutes, then 85°C for 15 minutes) and were then sequenced directly on both strands using the BigDyeH Terminator v1.1 cycle sequencing kit (Applied Biosystems) according to manufacturer's protocol and analysed by the ABI 3500 Genetic Analyzer (Applied Biosystem, CA, USA).

Results

Of the 159 patients, 90 were male and 69 female; ranged from 17 to 85 years of age (median 61.7). 24 patients were stage I, 36 stage II, 84 stage III and 15 stage IV.

KRAS mutational status was tested in 159 clinical samples of which 28 (17,6%) harboured at least one mutation at codon 12, 13 or 146.

Specific nucleotide and codon changes detected are listed in Table 1.

Mutations at codon 12 are the more frequent ones, followed by codon 13 and 146 ones. No point mutation was detected in KRAS at codon 61. 25 samples showed a mutation at codon 12, 2 at codon 13 and 1 at codon 146. The incidence of KRAS mutation was similar in men and women. The predominant mutations were G > A transition while the most frequent mutation was G12D (8.1% of all mutations). Representative electropherograms of KRAS wild type and G12D are shown in Figure 1.

Of the 131 KRAS wild type samples, 10 (6,3%) harboured a mutation at codon 600 in exon 15 of BRAF (V600E) (Table 2).

Table 1 Frequency of Mutations in KRAS codon 12, 13, 61 and 146 (N = 159)

Nucleotide change	Aminoacid change	N. of mutated cases (%)
KRAS codon 12		
c.35G > A	p.G12D	13 (8.1)
c.34G > A	p.G12S	1 (0.6)
c.35G > T	p.G12V	4 (2.5)
c.34G > T	p.G12C	4 (2.5)
c.35G > C	p.G12A	3 (1.9)
KRAS codon 13		
c.38G > A	p.G13D	2 (1.3)
KRAS codon 61		
/	/	0
KRAS codon 146		
c.436G > A	p.A146T	1 (0.6)

Representative electropherograms of BRAF wild type and with a V600E mutation are shown in Figure 2. In addition, our data confirmed that mutations in KRAS and BRAF are mutually exclusive.

All mutations found had previously been described to be oncogenically active and were found in the COSMIC (catalog of somatic mutations in cancer) database (Sanger Institute, Cambridge, UK).


No association between KRAS and BRAF mutations and various clinicopathological features such as age, gender, tumor differentiation, UICC classification was found (Table 3).

Discussion

The epidermal growth factor receptor (EGFR) plays a key role in the development and progression of CRC. It triggers a downstream signaling cascade such as RAS-RAF-MAPK and PI3K-AKT pathway, which are involved in cell proliferation, differentiation, survival and invasion. Among the activating mutations downstream of EGFR, KRAS and BRAF oncogenes participate in the MAPK pathway that mediates cellular response to growth signals [20]. This cascade is activated by the EGFR [21] that is overexpressed in 50-80% of colorectal tumors and therefore represent a suitable target for the anticancer therapies with monoclonal antibodies as cetuximab and panitumumab [22,23]. These molecules bind to the extracellular domain of EGFR leading to the inhibition of its downstream signaling.

The anti-EGFR therapies have shown to be effective only in a subset of patients with colorectal cancer [24]. To optimize the benefits and to reduce the risks of anti-EGFR therapies, the EGFR, as well as the molecules involved in its pathway, has been evaluated as potential marker to predict the treatment outcomes. Recent studies have demonstrated that mutations in the KRAS gene negatively predict the response to EGFR-targeted therapies in patients with metastatic colorectal cancer [25,26]. The KRAS mutations that are responsible for the synthesis of a permanently active KRAS protein [27,28] are predominately identified in the 12 and 13 codon of the gene [28]. Despite having a wild type KRAS, only 40-60% of the patients will respond to treatment [29]. The identification of the other important molecular determinants of response is therefore of an utmost importance.

The BRAF-activating mutations have been reported in various type of cancer: melanoma (70% of cases), thyroid (30-70%), ovarian (15-30%) and colorectal cancer (5-10%) [30,31]. All BRAF mutations occur within the kinase domain resulting in an elevated kinase activity of the BRAF protein. The p. Val600Glu (V600E) mutation is the most common mutation in the BRAF gene, found in approximately 80% of the cases [9,19]. Certain studies have demonstrated that wild type BRAF is required for response to panitumumab or cetuximab, suggesting that



BRAF should also be tested together with KRAS to select the patients who are most likely to benefit from the anti-EGFR therapy [19,32,33]. Our objective was the determine the frequency of most common mutations in KRAS gene (p.G12D, p.G12V, p.G12A, p.G12C, p.G12S, p.G12R, p.G13D, p.Q61H, p.Q61L, p.Q61R, p.A146T, p.A146V, p.A146P) together with the BRAF V600E mutation in Albanian patients with metastatic colorectal cancer.

In our study, we have evaluated KRAS and BRAF mutational status in 159 Albanian CRC patients using direct sequencing. The present study is first to provide data on frequency and type of KRAS and BRAF mutations of colorectal cancer in Albanian population; no data is present in the literature about this incidence.

In addition, we also tried correlate the presence of KRAS and BRAF mutations at codon 12, 13, 61, 146 and 600 with various clinicopathological features such as age, gender and grade as shown in Table 3.

In the present study, we did not find any significant correlations between these molecular events and various clinicopathological features, which may be partly attributable to the relatively small sample size.

In summary, our study reports that the incidence of KRAS mutation in Albanian colorectal cancer patients is

less frequent when compared with the data from literature (35-50%) [14,34-37].

This is probably due to the different methodology since we used direct sequencing and to small sample size.

Studies from various countries have analyzed the frequency of the type of KRAS point mutation in CRC. Most of the authors have identified the G > A transition as the most frequently found type of KRAS mutation [38,39]. In the current study, the G > A transition appeared also to be the predominant mutation, followed by G > T transversion. Among mutations in codons 12, the substitution of glycine with aspartate has been reported as the most frequent change. In accordance with our data, previous studies have usually identified the glycine to aspartate transition on codon 12 (p.G12D) as the most frequent mutation of KRAS [40-48].


The percentage of BRAF mutation is similar to the published data reporting the BRAF V600E mutation in the range of 5 to 10% [19,49].

Although the mutations in KRAS are considered to be a highly specific negative marker of response to cetuximab and panitumumab, the selection of patients for anti-EGFR treatment on such basis is not sensitive enough. Moreover, it has been reported that patients with activating mutations in RAS, in addition to KRAS exon 2, do not benefit from combined panitumumab plus FOLFOX4 chemotherapy [10].

Therefore, the BRAF mutational status is of utmost importance to be verified as another molecular determinant of response to anti-EGFR targeted monoclonal antibody therapy.

Table 2 Frequency of BRAF Mutations in Tumor Wild type for KRAS codon 12, 13, 61 and 146 (N = 131)

Nucleotide change	Aminoacid change	No. of mutated cases (%)
BRAF codon 600		
c.1799 > A	p. V600E	10 (6.3%)



In our group, we found 10 patients with the V600E mutation in BRAF. These 10 patients represent 6.3% of all tested patients.

All 10 patients with the V600E mutation in BRAF were wild-type KRAS, and no BRAF mutations were found in patients with a mutated KRAS genotype. This also is in concordance with previously published observations by

other authors that mutations in KRAS and BRAF are mutually exclusive [8].

Conclusions

In conclusion, we observed a frequency of 17,6% for mutations in exon 2, 3 and 4 of the KRAS oncogene, predominantly in codon 12. The G > A transition and G > T transversion were the most frequently observed mutations, with the G > T transversion confined to codon 12.

Summing up the results about the KRAS and the BRAF mutation carriers from our study, the portion of potentially non-responsive patients for the anti-EGFR treatment is 23,3%.

Thus, the anti-EGFR therapy could be beneficial for the majority of Albanian population.

The results of this study indicate that the types of KRAS mutations from CRC in Albania are similar to other countries but with a lower frequency.

A limitation of this study is the absence of data on NRAS mutations, considering that patients with RAS mutations (KRAS or NRAS) do not respond to anti-EGFR therapy.

These data should be confirmed on a larger study group and in prospective studies in order to determine whether these mutations contribute to progression of CRC.

Consent

Written informed consent was obtained from the patients for the publication of this study and any accompanying images.

Table 3 Correlation between KRAS, BRAF mutations and clinicopathological parameters in colorectal cancer (%)

Terms	All	Wild type	KRAS Mutation	BRAF Mutation
No.of patients	159	122	28 (17,6%)	10 (6,3%)
Median age	61,7			
Gender				
Male	90	69	18 (20%)	3 (3,3%)
Female	69	53	10 (14,5%)	7 (10,1%)
Differentiation				
Poor	12	11	/	1 (8,3%)
Moderate	76	57	17 (22%)	3 (3,9%)
Mucinoso	16	12	3 (18,7%)	1 (6,2%)
Well	52	39	8 (15,3%)	5 (9,6%)
UICC classification				
I	24	17	5 (20,8)	2 (8,3%)
IIA	36	26	7 (19,4)	3 (8,3%)
IIIA	10	9	1 (10%)	/
IIIB	70	55	11 (16%)	5 (7,1%)
IIIC	4	3	1 (25%)	/
IV	15	12	3 (20%)	/

Abbreviations

CRC: Colorectal cancer; EGFR: Epidermal growth factor receptor; TNM: Tumor, node and metastases; UICC: Classification of the Union for International Cancer Control staging; H&E: Haematoxylin & eosin; FFPE: Formalin-fixed paraffin-embedded.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

DM carried out the molecular studies and drafted the manuscript. RC carried out the molecular studies. SK participated in the design of the study and collected the samples. MA participated in the design of the study and collected the samples. CC participated in the design of the study. VC participated in the design of the study. MB participated in the design of the study. LM conceived the study, participated in its design and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgments

We would like to thank Giovanni Ferlito for his expert technical support.

Author details

¹IOM Ricerca Srl, Catania, Italy. ²Morphopathology Laboratories, Tirana, Albania. ³Department of Pathology, University of Tirana, Tirana, Albania. ⁴Department of Experimental Oncology, Mediterranean Institute of Oncology, Via Penninazzo 7, 95029 Viagrande, Catania, Italy. ⁵Division of Pathology, Centro di Riferimento Oncologico, Aviano, Italy. ⁶Department of Clinical Oncology, Centro di Riferimento Oncologico, Aviano, Italy.

Received: 6 August 2014 Accepted: 7 September 2014

Published online: 30 September 2014

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: **Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.** *Int J Cancer* 2010, **127**:2893–2917.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: **Cancer statistics, 2007.** *CA Cancer J Clin* 2007, **57**:43–66.
3. Russo A, Rizzo S, Bronte G, Silvestris N, Colucci G, Gebbia N, Bazan V, Fulfaro F: **The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway.** *Oncology* 2009, **77**(Suppl 1):57–68.
4. Vogelstein B, Fearon ER, Hamilton SR, Kem SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL: **Genetic alterations during colorectal tumor development.** *Engl J Med* 1998, **319**(9):525–532.
5. Porebska I, Harlozińska A, Bojarowski T: **Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas.** *Tumour Biol* 2000, **21**(2):105–115.
6. Reynolds NA, Wagstaff AJ: **Cetuximab in the treatment of metastatic colorectal cancer.** *Drugs* 2004, **64**(1):109–118.
7. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A: **Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.** *Cancer Res* 2007, **67**(6):2643–2648.
8. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE: **Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.** *Nature* 2002, **418**(6901):934.
9. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, et al: **Mutations of the BRAF gene in human cancer.** *Nature* 2002, **417**(6892):949–954.
10. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassme J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wierzok J, Sidhu R, Patterson SD: **Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.** *N Engl J Med* 2013, **369**(11):1023–1034.
11. Russo A, Bazan V, Agnese V, Rodolico V, Gebbia N: **Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.** *Ann Oncol* 2005, **16**(Suppl 4):iv44–iv49.
12. Edkins S, O'Meara S, Parker A, Stevens C, Reis M, Jones S, Greenman C, Davies H, Dalgliesh G, Forbes S, Hunter C, Smith R, Stephens P, Goldstraw P, Nicholson A, Chan TL, Velculescu VE, Yuen ST, Leung SY, Stratton MR, Futreal PA: **Recurrent KRAS codon 146 mutations in human colorectal cancer.** *Cancer Biol Ther* 2006, **5**(8):928–932.
13. Oliveira C, Westra JL, Arango D, Ollikainen M, Domingo E, Ferreira A, Velho S, Niessen R, Lagerstedt K, Alhopuro P, Laiho P, Veiga I, Teixeira MR, Ligtenberg M, Kleibeuker JH, Sijmons RH, Plukker JT, Imai K, Lage P, Hamelin R, Albuquerque C, Schwartz S Jr, Lindblom A, Peltomaki P, Yamamoto H, Aaltonen LA, Seruca R, Hofstra RM: **Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status.** *Hum Mol Genet* 2004, **13**(19):2303–2311.
14. Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian ZR, Liao X, Nishihara R, Jung S, Wu K, Noshko K, Wang YE, Peng S, Bass AJ, Haigis KM, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S: **Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.** *Mol Cancer* 2014, **13**:135.
15. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A: **Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.** *J Natl Cancer Inst* 2009, **101**(19):1308–1324.
16. Jones S, Chen WD, Parmigiani G, Diehl F, Beerwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B, Willis J, Markowitz SD: **Comparative lesion sequencing provides insights into tumor evolution.** *Proc Natl Acad Sci U S A* 2008, **105**(11):4283–4288.
17. Risio M, Malacarne D, Giaretti W: **KRAS transitions and villous growth in colorectal adenomas.** *Cell Oncol* 2005, **27**(5–6):363–366.
18. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalczberg JR: **K-ras mutations and benefit from cetuximab in advanced colorectal cancer.** *N Engl J Med* 2008, **359**(17):1757–1765.
19. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A: **Wild Type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.** *J Clin Oncol* 2008, **26**(35):5705–5712.
20. Peyssonnaud C, Eychene A: **The Raf/MEK/ERK pathway: new concepts of activation.** *Biol Cell* 2001, **93**(1–2):53–62.
21. Harari PM, Allen GW, Bonner JA: **Biology of interactions: anti-epidermal growth factor receptor agents.** *J Clin Oncol* 2007, **25**(26):4057–4065.
22. Hemming AW, Davis NL, Kluftinger A, Robinson B, Quenville NF, Liseman B, LeRiche J: **Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and ki-67.** *J Surg Oncol* 1992, **51**(3):147–152.
23. Bonomi PD, Buckingham L, Coon J: **Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.** *Clin Cancer Res* 2007, **13**(15Pt2):s4606–s4612.
24. Dassonville O, Bozec A, Fischel JL, Milano G: **EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.** *Crit Rev Oncol Hematol* 2007, **62**(1):53–61.
25. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD: **Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.** *J Clin Oncol* 2008, **26**(10):1626–1634.
26. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S: **KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.** *Ann Oncol* 2008, **19**(3):508–515.
27. Zenker M, Lehmann K, Schulz AL: **Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations.** *J Med Genet* 2007, **44**(2):131–135.
28. Van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Fléjou JF, Plato Hansen T, de Hertogh G, Jares P, Langner C, Hoeffler G, Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G, Ensari A: **KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma proposal for an European quality assurance program.** *Virchows Arch* 2008, **453**(5):417–431.

29. Linardou H1, Dahabreh IJ, Kanaklopiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S: **Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.** *Lancet Oncol* 2008, **9**(10):962–972.
30. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C: **BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.** *Mol Cancer Res* 2008, **6**(5):751–759.
31. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhönen S, Hemminki K: **BRAF mutations in metastatic melanoma: a possible association with clinical outcome.** *Clin Cancer Res* 2003, **9**(9):3362–3368.
32. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F: **KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.** *Br J Cancer* 2009, **101**(4):715–721.
33. Laurent-Puig P, Cayre A, Manceau G: **Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.** *J Clin Oncol* 2009, **27**(35):5924–5930.
34. Ozen F, Ozdemir S, Zemheri E, Hacimuto G, Silan F, Ozdemir O: **The protooncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population.** *Genet Test Mol Biomarkers* 2013, **17**(2):135–139.
35. Rako I, J. Jakic-Razumovic J, Katalinic D, Sertic J, Plestina S: **Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients.** *Neoplasma* 2012, **59**(4):376–383.
36. Bozzao C, Varvara D, Pigionica M, Bagnulo R, Forte G, Patruno M, Russo S, Piscitelli D, Stella A, Resta N: **Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients.** *Int J Biol Markers* 2012, **27**(4):e366–e374.
37. Vaughn CP, Zobel SD, Furtado LV, Baker CL, Samowitz WS: **Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.** *Genes Chromosomes Cancer* 2011, **50**(5):307–312.
38. Topal MD: **DNA repair, oncogenes and carcinogenesis.** *Carcinogenesis* 1998, **9**(5):691–696.
39. Zarbl H, Sukumar S, Arthur AV, Martin-Zanca D, Barbacid M: **Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats.** *Nature* 1985, **315**(6018):382–385.
40. Adams R, Meade A, Wasan H, Griffiths G, Maughan T: **Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.** *Expert Rev Anticancer Ther* 2008, **8**:1237–1245.
41. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA: **Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study.** *J Natl Cancer Inst* 1998, **90**(9):675–684.
42. Barault L1, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, Lièvre A, Cortet M, Bouvier AM, Rat P, Roignant P, Faivre J, Laurent-Puig P, Piard F: **Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.** *Int J Cancer* 2008, **122**(10):2255–2259.
43. Cerottini JP, Caplin S, Saraga E, Givel JC, Benhattar J: **The type of K-ras mutation determines prognosis in colorectal cancer.** *Am J Surg* 1998, **175**(3):198–202.
44. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboué R, Tuech JJ, Queuniet AM, Paillet B, Sabourin JC, Michot F, Michel P, Frebourg T: **Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.** *Br J Cancer* 2007, **96**(8):1166–1169.
45. Kressner U1, Bjørheim J, Westring S, Wahlberg SS, Pählman L, Glimelius B, Lindmark G, Lindblom A, Børresen-Dale AL: **Ki-ras mutations and prognosis in colorectal cancer.** *Eur J Cancer* 1998, **34**(4):518–521.
46. Moerkerk P, Arends JW, Van Driel M, De Bruine A, De Goeij A, Ten Kate J: **Type and number of Ki-ras point mutations relate to stage of human colorectal cancer.** *Cancer Res* 1994, **54**(13):3376–3378.
47. Span M, Moerkerk PT, De Goeij AF, Arends JW: **A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients.** *Int J Cancer* 1996, **69**(3):241–245.
48. Urošević N, Krtolica K, Skaro-Milic A, Knezevic-Usaj S, Dujic A: **Prevalence of G-to-T transversions among K-ras oncogene mutations in human colorectal tumors in Yugoslavia.** *Int J Cancer* 1993, **54**(2):249–254.
49. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R, Leung SY: **Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.** *Cancer Res* 2002, **62**(22):6451–6455.

doi:10.1186/s13000-014-0187-7

Cite this article as: Martinetti et al.: KRAS and BRAF mutational status in colon cancer from Albanian patients. *Diagnostic Pathology* 2014 **9**:187.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

